Malignant Tumors Arising in Inflammatory Bowel Disease

  • Thomas A. Ullman


Colorectal Cancer Inflammatory Bowel Disease Ulcerative Colitis Primary Sclerosing Cholangitis Colitis Patient 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Itzkowitz SH, Yio X. Inflammation and cancer IV. Colorectal cancer in inflammatory bowel disease: The role of inflammation. Am J Physiol Gastrointest Liver Physiol 2004;287:G7–17.PubMedCrossRefGoogle Scholar
  2. 2.
    Itzkowitz SH. Inflammatory bowel disease and cancer. Gastroenterol Clin North Am 1997;26:129–39.PubMedCrossRefGoogle Scholar
  3. 3.
    Itzkowitz SH, Harpaz N. Diagnosis and management of dysplasia in patients with inflammatory bowel diseases. Gastroenterology 2004;126:1634–48.PubMedCrossRefGoogle Scholar
  4. 4.
    Brentnall TA, Crispin DA, Rabinovitch PS, Haggitt RC, Rubin CE, Stevens AC, Burmer GC. Mutations in the p53 gene: An early marker of neoplastic progression in ulcerative colitis. Gastroenterology 1994;107:369–78.PubMedGoogle Scholar
  5. 5.
    Brentnall TA, Crispin DA, Bronner MP, Cherian SP, Hueffed M, Rabinovitch PS, Rubin CE, Haggitt RC, Boland CR. Microsatellite instability in nonneoplastic mucosa from patients with chronic ulcerative colitis. Cancer Res 1996;56:1237–40.PubMedGoogle Scholar
  6. 6.
    Suzuki H, Harpaz N, Tarmin L, Yin J, Jiang HY, Bell JD, Hontanosas M, Groisman GM, Abraham JM, Meltzer SJ. Microsatellite instability in ulcerative colitis-associated colorectal dysplasias and cancers. Cancer Res 1994;54:4841–4.PubMedGoogle Scholar
  7. 7.
    Crohn BB, Rosenberg H. The sigmoidoscopic picture of chronic ulcerative colitis. Am J Med Sci 1925;170:220–228.CrossRefGoogle Scholar
  8. 8.
    Bargen TA. Chronic ulcerative colitis associated with malignant disease. Arch Surg 1928;17:862–868.Google Scholar
  9. 9.
    Devroede GJ, Taylor WF, Sauer WG, Jackman RJ, Stickler GB. Cancer risk and life expectancy of children with ulcerative colitis. N Engl J Med 1971;285:17–21.PubMedCrossRefGoogle Scholar
  10. 10.
    Bargen JA, Gage RP. Carcinoma and ulcerative colitis:Prognosis. Gastro 1960;39:385–392.Google Scholar
  11. 11.
    Slaney G, Brooke BN. Cancer in ulcerative colitis. Lancet 1959;2:694–698.PubMedCrossRefGoogle Scholar
  12. 12.
    Rozen P, et al. Low incidence of significant dysplasia in a successful endoscopic surveillance program of patients with ulcerative colitis. Gastroenterology.1995;108:1361–70.PubMedCrossRefGoogle Scholar
  13. 13.
    Ekbom A, Helmick C, Zack M, Adami HO. Ulcerative colitis and colorectal cancer. A population-based study. N Engl J Med 1990;323:1228–33.PubMedCrossRefGoogle Scholar
  14. 14.
    Gilat T, Fireman Z, Grossman A, Hacohen D, Kadish U, Ron E, Rozen P, Lilos P. Colorectal cancer in patients with ulcerative colitis. A population study in central Israel.Gastroenterology 1988;94:870–7.PubMedGoogle Scholar
  15. 15.
    Leidenius M, Kellokumpu I, Husa A, Riihela M, Sipponen P. Dysplasia and carcinoma in longstanding ulcerative colitis: An endoscopic and histological surveillance programme. Gut 1991;32:1521–5.PubMedCrossRefGoogle Scholar
  16. 16.
    Langholz E, Munkholm P, Davidsen M, Binder V. Colorectal cancer risk and mortality in patients with ulcerative colitis. Gastroenterology 1992;103:1444–51.PubMedGoogle Scholar
  17. 17.
    Eaden JA, Abrams KR, Mayberry JF. The risk of colorectal cancer in ulcerative colitis: A meta-analysis. Gut 2001;48:526–35.PubMedCrossRefGoogle Scholar
  18. 18.
    Winther KV, Jess T, Langholz E, Munkholm P, Binder V. Long-term risk of cancer in ulcerative colitis: A population-based cohort study from Copenhagen County. Clin Gastroenterol Hepatol 2004;2:1088–95.PubMedCrossRefGoogle Scholar
  19. 19.
    Lakatos L, Mester G, Erdelyi Z, David G, Pandur T, Balogh M, Fischer S, Vargha P, Lakatos PL. Risk factors for ulcerative colitis-associated colorectal cancer in a Hungarian cohort of patients with ulcerative colitis: Results of a population-based study. Inflamm Bowel Dis 2006;12:205–11.PubMedCrossRefGoogle Scholar
  20. 20.
    Bernstein CN, Blanchard JF, Kliewer E, Wajda A. Cancer risk in patients with inflammatory bowel disease: A population-based study. Cancer 2001;91:854–62.PubMedCrossRefGoogle Scholar
  21. 21.
    Jess T, Loftus EV, Jr., Velayos FS, Harmsen WS, Zinsmeister AR, Smyrk TC, Schleck CD, Tremaine WJ, Melton LJ, 3rd, Munkholm P, Sandborn WJ. Risk of intestinal cancer in inflammatory bowel disease: A population-based study from olmsted county, Minnesota. Gastroenterology 2006;130:1039–46.PubMedCrossRefGoogle Scholar
  22. 22.
    Rutter MD, Saunders BP, Wilkinson KH, Rumbles S, Schofield G, Kamm MA, Williams CB, Price AB, Talbot IC, Forbes A. Thirty-year analysis of a colonoscopic surveillance program for neoplasia in ulcerative colitis. Gastroenterology 2006;130:1030–8.PubMedCrossRefGoogle Scholar
  23. 23.
    Edwards F, Truelove S. The course and prognosis of ulcerative colitis. III and IV. Gut 1964;5:1.PubMedCrossRefGoogle Scholar
  24. 24.
    Gyde SN, Prior P, Allan RN, Stevens A, Jewell DP, Truelove SC, Lofberg R, Brostrom O, Hellers G. Colorectal cancer in ulcerative colitis: A cohort study of primary referrals from three centres. Gut 1988;29:206–17.PubMedCrossRefGoogle Scholar
  25. 25.
    Greenstein AJ, Sachar DB, Smith H, Pucillo A, Papatestas AE, Kreel I, Geller SA, Janowitz HD, Aufses AH, Jr. Cancer in universal and left-sided ulcerative colitis: Factors determining risk. Gastroenterology 1979;77:290–4.PubMedGoogle Scholar
  26. 26.
    Langholz E, Munkholm P, Davidsen M, Nielsen OH, Binder V. Changes in extent of ulcerative colitis: A study on the course and prognostic factors. Scand J Gastroenterol 1996;31:260–6.PubMedCrossRefGoogle Scholar
  27. 27.
    Katzka I, Brody RS, Morris E, Katz S. Assessment of colorectal cancer risk in patients with ulcerative colitis: Experience from a private practice. Gastroenterology 1983;85:22–9.PubMedGoogle Scholar
  28. 28.
    Mir-Madjlessi SH, Farmer RG, Easley KA, Beck GJ. Colorectal and extracolonic malignancy in ulcerative colitis. Cancer 1986;58:1569–74.PubMedCrossRefGoogle Scholar
  29. 29.
    Mathy C, Schneider K, Chen YY, Varma M, Terdiman JP, Mahadevan U. Gross versus microscopic pancolitis and the occurrence of neoplasia in ulcerative colitis. Inflamm Bowel Dis 2003;9:351–5.PubMedCrossRefGoogle Scholar
  30. 30.
    Gurbuz AK, Giardiello FM, Bayless TM. Colorectal neoplasia in patients with ulcerative colitis and primary sclerosing cholangitis. Dis Colon Rectum 1995;38:37–41.PubMedCrossRefGoogle Scholar
  31. 31.
    Loftus EV, Jr., Sandborn WJ, Tremaine WJ, Mahoney DW, Zinsmeister AR, Offord KP, Melton LJ, 3rd. Risk of colorectal neoplasia in patients with primary sclerosing cholangitis [see comments]. Gastroenterology 1996;110:432–40.PubMedCrossRefGoogle Scholar
  32. 32.
    Nuako KW, Ahlquist DA, Sandborn WJ, Mahoney DW, Siems DM, Zinsmeister AR. Primary sclerosing cholangitis and colorectal carcinoma in patients with chronic ulcerative colitis:A case-control study. Cancer 1998;82:822–6.Google Scholar
  33. 33.
    Brentnall TA, Haggitt RC, Rabinovitch PS, Kimmey MB, Bronner MP, Levine DS, Kowdley KV, Stevens AC, Crispin DA, Emond M, Rubin CE. Risk and natural history of colonic neoplasia in patients with primary sclerosing cholangitis and ulcerative colitis. Gastroenterology 1996;110:331–8.PubMedCrossRefGoogle Scholar
  34. 34.
    Broome U, Lindberg G, Lofberg R. Primary sclerosing cholangitis in ulcerative colitis–a risk factor for the development of dysplasia and DNA aneuploidy? Gastroenterology 1992;102:1877–80.PubMedGoogle Scholar
  35. 35.
    Broome U, Lofberg R, Veress B, Eriksson LS. Primary sclerosing cholangitis and ulcerative colitis:Evidence for increased neoplastic potential. Hepatology 1995;22:1404–8.PubMedGoogle Scholar
  36. 36.
    D’Haens GR, Lashner BA, Hanauer SB. Pericholangitis and sclerosing cholangitis are risk factors for dysplasia and cancer in ulcerative colitis. Am J Gastroenterol 1993;88:1174–8.PubMedGoogle Scholar
  37. 37.
    Marchesa P, Lashner BA, Lavery IC, Milsom J, Hull TL, Strong SA, Church JM, Navarro G, Fazio VW. The risk of cancer and dysplasia among ulcerative colitis patients with primary sclerosing cholangitis. Am J Gastroenterol 1997;92:1285–8.PubMedGoogle Scholar
  38. 38.
    Kornfeld D, Ekbom A, Ihre T. Is there an excess risk for colorectal cancer in patients with ulcerative colitis and concomitant primary sclerosing cholangitis? A population based study. Gut 1997;41:522–5.PubMedCrossRefGoogle Scholar
  39. 39.
    Burt RW. Familial risk and colorectal cancer. Gastroenterol Clin North Am 1996;25:793–803.PubMedCrossRefGoogle Scholar
  40. 40.
    Lashner BA, Heidenreich PA, Su GL, Kane SV, Hanauer SB. Effect of folate supplementation on the incidence of dysplasia and cancer in chronic ulcerative colitis. A case-control study. Gastroenterology 1989;97:255–9.PubMedGoogle Scholar
  41. 41.
    Lashner BA, Provencher KS, Seidner DL, Knesebeck A, Brzezinski A. The effect of folic acid supplementation on the risk for cancer or dysplasia in ulcerative colitis. Gastroenterology 1997;112:29–32.PubMedCrossRefGoogle Scholar
  42. 42.
    Nuako KW, Ahlquist DA, Mahoney DW, Schaid DJ, Siems DM, Lindor NM. Familial predisposition for colorectal cancer in chronic ulcerative colitis:A case-control study. Gastroenterology 1998;115:1079–83.PubMedCrossRefGoogle Scholar
  43. 43.
    Askling J, Dickman PW, Karlen P, Brostrom O, Lapidus A, Lofberg R, Ekbom A. Family history as a risk factor for colorectal cancer in inflammatory bowel disease. Gastroenterology 2001;120:1356–62.PubMedCrossRefGoogle Scholar
  44. 44.
    Eaden J, Abrams K, Ekbom A, Jackson E, Mayberry J. Colorectal cancer prevention in ulcerative colitis:A case-control study. Aliment Pharmacol Ther 2000;14:145–53.PubMedCrossRefGoogle Scholar
  45. 45.
    Rutter M, Saunders B, Wilkinson K, Rumbles S, Schofield G, Kamm M, Williams C, Price A, Talbot I, Forbes A. Severity of inflammation is a risk factor for colorectal neoplasia in ulcerative colitis. Gastroenterology 2004;126(2):451–9.PubMedCrossRefGoogle Scholar
  46. 46.
    Bansali R, Itzkowitz S, Harpaz N, Hossein S, Matula S, Bodian C, Ullman T. Severity of Inflammation Predicts Progression to Colorectal Neoplasia in Ulcerative Colitis, In American College of Gastroenterology, Honolulu, HI, 2005.Google Scholar
  47. 47.
    Pinczowski D, Ekbom A, Baron J, Yuen J, Adami HO. Risk factors for colorectal cancer in patients with ulcerative colitis: A case-control study. Gastroenterology 1994;107:117–20.PubMedGoogle Scholar
  48. 48.
    Tung BY, Emond MJ, Haggitt RC, Bronner MP, Kimmey MB, Kowdley KV, Brentnall TA. Ursodiol use is associated with lower prevalence of colonic neoplasia in patients with ulcerative colitis and primary sclerosing cholangitis. Ann Intern Med 2001;134:89–95.PubMedGoogle Scholar
  49. 49.
    van Staa TP, Card T, Logan RF, Leufkens HG. 5-Aminosalicylate use and colorectal cancer risk in inflammatory bowel disease: A large epidemiological study. Gut 2005;54:1573–8.PubMedCrossRefGoogle Scholar
  50. 50.
    Rubin DT, LoSavio A, Yadron N, Huo D, Hanauer SB. Aminosalicylate therapy in the prevention of dysplasia and colorectal cancer in ulcerative colitis. Clin Gastroenterol Hepatol 2006;4:1346–50.PubMedCrossRefGoogle Scholar
  51. 51.
    Bernstein CN, Blanchard JF, Metge C, Yogendran M. Does the use of 5-aminosalicylates in inflammatory bowel disease prevent the development of colorectal cancer? Am J Gastroenterol 2003;98:2784–8.PubMedCrossRefGoogle Scholar
  52. 52.
    Terdiman JP, Steinbuch M, Blumentals WA, Ullman TA, Rubin DT. 5-Aminosalicylic acid therapy and the risk of colorectal cancer among patients with inflammatory bowel disease. Inflamm Bowel Dis 2007 Apr;13(4):367–71.CrossRefGoogle Scholar
  53. 53.
    Velayos FS, Terdiman JP, Walsh JM. Effect of 5-aminosalicylate use on colorectal cancer and dysplasia risk:A systematic review and metaanalysis of observational studies. Am J Gastroenterol 2005;100:1345–53.PubMedCrossRefGoogle Scholar
  54. 54.
    Pardi DS, Loftus EV, Jr., Kremers WK, Keach J, Lindor KD. Ursodeoxycholic acid as a chemopreventive agent in patients with ulcerative colitis and primary sclerosing cholangitis. Gastroenterology 2003;124:889–93.PubMedCrossRefGoogle Scholar
  55. 55.
    Choi PM, Nugent FW, Schoetz DJ, Jr., Silverman ML, Haggitt RC. Colonoscopic surveillance reduces mortality from colorectal cancer in ulcerative colitis. Gastroenterology 1993;105:418–24.PubMedGoogle Scholar
  56. 56.
    Connell WR, Lennard-Jones JE, Williams CB, Talbot IC, Price AB, Wilkinson KH. Factors affecting the outcome of endoscopic surveillance for cancer in ulcerative colitis [see comments]. Gastroenterology 1994;107:934–44.PubMedGoogle Scholar
  57. 57.
    Becker JM. Surgical therapy for ulcerative colitis and Crohn disease. Gastroenterol Clin North Am 1999;28:371–90, viii–ix.Google Scholar
  58. 58.
    Stern H, Walfisch S, Mullen B, McLeod R, Cohen Z. Cancer in an ileoanal reservoir: A new late complication? Gut 1990;31:473–5.PubMedCrossRefGoogle Scholar
  59. 59.
    Thompson-Fawcett MW, Marcus V, Redston M, Cohen Z, McLeod RS. Risk of dysplasia in long-term ileal pouches and pouches with chronic pouchitis. Gastroenterology 2001;121:275–81.PubMedCrossRefGoogle Scholar
  60. 60.
    Morson BC, Pang LS. Rectal biopsy as an aid to cancer control in ulcerative colitis. Gut 1967;8:423–34.PubMedCrossRefGoogle Scholar
  61. 61.
    Cook MG, Goligher JC. Carcinoma and epithelial dysplasia complicating ulcerative colitis. Gastroenterology 1975;68:1127–36.PubMedGoogle Scholar
  62. 62.
    Ransohoff DF, Riddell RH, Levin B. Ulcerative colitis and colonic cancer. Problems in assessing the diagnostic usefulness of mucosal dysplasia. Dis Colon Rectum 1985;28:383–8.PubMedCrossRefGoogle Scholar
  63. 63.
    Taylor BA, Pemberton JH, Carpenter HA, Levin KE, Schroeder KW, Welling DR, Spencer MP, Zinsmeister AR. Dysplasia in chronic ulcerative colitis:Implications for colonoscopic surveillance. Dis Colon Rectum 1992;35:950–6.PubMedCrossRefGoogle Scholar
  64. 64.
    Dickinson RJ, Dixon MF, Axon AT. Colonoscopy and the detection of dysplasia in patients with longstanding ulcerative colitis. Lancet 1980;2:620–2.PubMedCrossRefGoogle Scholar
  65. 65.
    Levin B, Lennard-Jones J, Riddell RH, Sachar D, Winawer SJ. Surveillance of patients with chronic ulcerative colitis. WHO Collaborating Centre for the Prevention of Colorectal Cancer. Bull World Health Organ 1991;69:121–6.PubMedGoogle Scholar
  66. 66.
    Kornbluth A, Sachar DB. Ulcerative colitis practice guidelines in adults. American College of Gastroenterology, Practice Parameters Committee. Am J Gastroenterol 1997;92:204–11.PubMedGoogle Scholar
  67. 67.
    Brostrom O, Lofberg R, Ost A, Reichard H. Cancer surveillance of patients with longstanding ulcerative colitis: A clinical, endoscopical, and histological study. Gut 1986;27:1408–13.PubMedCrossRefGoogle Scholar
  68. 68.
    Blackstone MO, Riddell RH, Rogers BH, Levin B. Dysplasia-associated lesion or mass (DALM) detected by colonoscopy in long-standing ulcerative colitis: An indication for colectomy. Gastroenterology 1981;80:366–74.PubMedGoogle Scholar
  69. 69.
    Lashner BA, Silverstein MD, Hanauer SB. Hazard rates for dysplasia and cancer in ulcerative colitis. Results from a surveillance program. Dig Dis Sci 1989;34:1536–41.PubMedCrossRefGoogle Scholar
  70. 70.
    Lashner BA, Kane SV, Hanauer SB. Colon cancer surveillance in chronic ulcerative colitis: Historical cohort study. Am J Gastroenterol 1990;85:1083–7.PubMedGoogle Scholar
  71. 71.
    Lennard-Jones JE, Morson BC, Ritchie JK, Shove DC, Williams CB. Cancer in colitis: Assessment of the individual risk by clinical and histological criteria. Gastroenterology 1977;73:1280–9.PubMedGoogle Scholar
  72. 72.
    Lennard-Jones JE, Melville DM, Morson BC, Ritchie JK, Williams CB. Precancer and cancer in extensive ulcerative colitis: Findings among 401 patients over 22 years. Gut 1990;31:800–6.PubMedCrossRefGoogle Scholar
  73. 73.
    Lofberg R, Brostrom O, Karlen P, Tribukait B, Ost A. Colonoscopic surveillance in long-standing total ulcerative colitis–a 15-year follow-up study. Gastroenterology 1990;99:1021–31.PubMedGoogle Scholar
  74. 74.
    Lynch DA, Lobo AJ, Sobala GM, Dixon MF, Axon AT. Failure of colonoscopic surveillance in ulcerative colitis. Gut 1993;34:1075–80.PubMedCrossRefGoogle Scholar
  75. 75.
    Nugent FW, Haggitt RC, Gilpin PA. Cancer surveillance in ulcerative colitis. Gastroenterology 1991;100:1241–8.PubMedGoogle Scholar
  76. 76.
    Rutegard J, Ahsgren L, Stenling R, Janunger KG. Ulcerative colitis. Cancer surveillance in an unselected population. Scand J Gastroenterol 1988;23:139–45.PubMedGoogle Scholar
  77. 77.
    Woolrich AJ, DaSilva MD, Korelitz BI. Surveillance in the routine management of ulcerative colitis: The predictive value of low-grade dysplasia. Gastroenterology 1992;103:431–8.PubMedGoogle Scholar
  78. 78.
    Ullman T, Croog V, Harpaz N, Sachar D, Itzkowitz S. Progression of flat low-grade dysplasia to advanced neoplasia in patients with ulcerative colitis. Gastroenterology 2003;125:1311–9.PubMedCrossRefGoogle Scholar
  79. 79.
    Karlen P, Kornfeld D, Brostrom O, Lofberg R, Persson PG, Ekbom A. Is colonoscopic surveillance reducing colorectal cancer mortality in ulcerative colitis? A population based case control study. Gut 1998;42:711–4.PubMedCrossRefGoogle Scholar
  80. 80.
    Velayos FS, Loftus EV, Jr., Jess T, Harmsen WS, Bida J, Zinsmeister AR, Tremaine WJ, Sandborn WJ. Predictive and protective factors associated with colorectal cancer in ulcerative colitis: A case-control study. Gastroenterology 2006;130:1941–9.PubMedCrossRefGoogle Scholar
  81. 81.
    Gage TP. Managing the cancer risk in chronic ulcerative colitis. A decision- analytic approach. J Clin Gastroenterol 1986;8:50–7.PubMedCrossRefGoogle Scholar
  82. 82.
    Delco F, Sonnenberg A. A decision analysis of surveillance for colorectal cancer in ulcerative colitis. Gut 2000;46:500–6.PubMedCrossRefGoogle Scholar
  83. 83.
    Inadomi JM. Cost-effectiveness of colorectal cancer surveillance in ulcerative colitis. Scand J Gastroenterol Suppl 2003:17–21.Google Scholar
  84. 84.
    Delco F, Sonnenberg A. A decision analysis of surveillance for colorectal cancer in ulcerative colitis. Gut 2000;46:500–6.PubMedCrossRefGoogle Scholar
  85. 85.
    Provenzale D, Kowdley KV, Arora S, Wong JB. Prophylactic colectomy or surveillance for chronic ulcerative colitis? A decision analysis [see comments]. Gastroenterology 1995;109:1188–96.PubMedCrossRefGoogle Scholar
  86. 86.
    Riddell RH, Goldman H, Ransohoff DF, Appelman HD, Fenoglio CM, Haggitt RC, Ahren C, Correa P, Hamilton SR, Morson BC, et al. Dysplasia in inflammatory bowel disease:Standardized classification with provisional clinical applications. Hum Pathol 1983;14:931–68.PubMedCrossRefGoogle Scholar
  87. 87.
    Eaden J, Abrams K, McKay H, Denley H, Mayberry J. Inter-observer variation between general and specialist gastrointestinal pathologists when grading dysplasia in ulcerative colitis. J Pathol 2001;194:152–7.PubMedCrossRefGoogle Scholar
  88. 88.
    Dixon MF, Brown LJ, Gilmour HM, Price AB, Smeeton NC, Talbot IC, Williams GT. Observer variation in the assessment of dysplasia in ulcerative colitis. Histopathology 1988;13:385–97.PubMedCrossRefGoogle Scholar
  89. 89.
    Melville DM, Jass JR, Morson BC, Pollock DJ, Richman PI, Shepherd NA, Ritchie JK, Love SB, Lennard-Jones JE. Observer study of the grading of dysplasia in ulcerative colitis:Comparison with clinical outcome. Hum Pathol 1989;20:1008–14.PubMedCrossRefGoogle Scholar
  90. 90.
    Connell WR, Talbot IC, Harpaz N, Britto N, Wilkinson KH, Kamm MA, Lennard-Jones JE. Clinicopathological characteristics of colorectal carcinoma complicating ulcerative colitis. Gut 1994;35:1419–23.PubMedCrossRefGoogle Scholar
  91. 91.
    Ullman TA, Loftus EV, Jr., Kakar S, Burgart LJ, Sandborn WJ, Tremaine WJ. The fate of low grade dysplasia in ulcerative colitis. Am J Gastroenterol 2002;97:922–7.PubMedCrossRefGoogle Scholar
  92. 92.
    Brentnall T, Bronner M, Rubin C, Rabinovitch P, Kimmey M, Kowdley K, Edmond M, Haggitt R. Natural history and management of low-grade dysplasia in ulcerative colitis. Gastroenterology 1999;116:A382.Google Scholar
  93. 93.
    Befrits R, Ljung T, Jaramillo E, Rubio C. Low grade dysplasia in flat colonic mucosa in patients with extensive longstanding inflammatory bowel disease – a follow-up study. Gastroenterology 1999;116:A376.Google Scholar
  94. 94.
    Befrits R, Ljung T, Jaramillo E, Rubio C. Low-grade dysplasia in extensive, long-standing inflammatory bowel disease: A follow-up study. Dis Colon Rectum 2002;45:615–20.PubMedCrossRefGoogle Scholar
  95. 95.
    Lim CH, Dixon MF, Vail A, Forman D, Lynch DA, Axon AT. Ten year follow up of ulcerative colitis patients with and without low grade dysplasia. Gut 2003;52:1127–32.PubMedCrossRefGoogle Scholar
  96. 96.
    Rubin CE, Haggitt RC, Burmer GC, Brentnall TA, Stevens AC, Levine DS, Dean PJ, Kimmey M, Perera DR, Rabinovitch PS. DNA aneuploidy in colonic biopsies predicts future development of dysplasia in ulcerative colitis. Gastroenterology 1992;103:1611–20.PubMedGoogle Scholar
  97. 97.
    Eaden JA, Ward BA, Mayberry JF. How gastroenterologists screen for colonic cancer in ulcerative colitis: An analysis of performance. Gastrointest Endosc 2000;51:123–8.PubMedCrossRefGoogle Scholar
  98. 98.
    Ullman T, White J, Harpaz N, Itzkowitz S. Assessment of Biopsy Practices in Colonoscopic Surveillance in Ulcerative Colitis. Gastroenterology 2001;120:A–446.CrossRefGoogle Scholar
  99. 99.
    Rubin PH, et al. Colonoscopic polypectomy in chronic colitis:Conservative management after endoscopic resection of dysplastic polyps. Gastroenterology. 1999;117:1295–300.PubMedCrossRefGoogle Scholar
  100. 100.
    Engelsgjerd M, Farraye FA, Odze RD. Polypectomy may be adequate treatment for adenoma-like dysplastic lesions in chronic ulcerative colitis [see comments]. Gastroenterology 1999;117:1288–94; discussion 1488–91.PubMedCrossRefGoogle Scholar
  101. 101.
    Odze RD, Farraye FA, Hecht JL, Hornick JL. Long-term follow-up after polypectomy treatment for adenoma-like dysplastic lesions in ulcerative colitis. Clin Gastroenterol Hepatol 2004;2:534–41.PubMedCrossRefGoogle Scholar
  102. 102.
    Vieth M, Behrens H, Stolte M. Sporadic adenoma in ulcerative colitis: Endoscopic resection is an adequate treatment. Gut 2006;55:1151–5.PubMedCrossRefGoogle Scholar
  103. 103.
    Selaru FM, Xu Y, Yin J, Zou T, Liu TC, Mori Y, Abraham JM, Sato F, Wang S, Twigg C, Olaru A, Shustova V, Leytin A, Hytiroglou P, Shibata D, Harpaz N, Meltzer SJ. Artificial neural networks distinguish among subtypes of neoplastic colorectal lesions. Gastro 2002;122:606–613.CrossRefGoogle Scholar
  104. 104.
    Bernstein CN, Weinstein WM, Levine DS, Shanahan F. Physicians’ perceptions of dysplasia and approaches to surveillance colonoscopy in ulcerative colitis. Am J Gastroenterol 1995;90:2106–14.PubMedGoogle Scholar
  105. 105.
    Rubin DT, Turner JR. Surveillance of dysplasia in inflammatory bowel disease:The gastroenterologist-pathologist partnership. Clin Gastroenterol Hepatol 2006;4:1309–13.PubMedCrossRefGoogle Scholar
  106. 106.
    Itzkowitz SH, Present DH. Consensus conference: Colorectal cancer screening and surveillance in inflammatory bowel disease. Inflamm Bowel Dis 2005;11:314–21.PubMedCrossRefGoogle Scholar
  107. 107.
    Kiesslich R, Fritsch J, Holtmann M, Koehler HH, Stolte M, Kanzler S, Nafe B, Jung M, Galle PR, Neurath MF. Methylene blue-aided chromoendoscopy for the detection of intraepithelial neoplasia and colon cancer in ulcerative colitis. Gastroenterology 2003;124:880–8.PubMedCrossRefGoogle Scholar
  108. 108.
    Rutter MD, Saunders BP, Schofield G, Forbes A, Price AB, Talbot IC. Pancolonic indigo carmine dye spraying for the detection of dysplasia in ulcerative colitis. Gut 2004;53:256–60.PubMedCrossRefGoogle Scholar
  109. 109.
    Gollop JH, Phillips SF, Melton LJ, 3rd, Zinsmeister AR. Epidemiologic aspects of Crohn disease: A population based study in Olmsted County, Minnesota, 1943–1982. Gut 1988;29:49–56.PubMedCrossRefGoogle Scholar
  110. 110.
    Munkholm P, Langholz E, Davidsen M, Binder V. Intestinal cancer risk and mortality in patients with Crohn disease. Gastroenterology 1993;105:1716–23.PubMedGoogle Scholar
  111. 111.
    Weedon DD, Shorter RG, Ilstrup DM, Huizenga KA, Taylor WF. Crohn disease and cancer. N Engl J Med 1973;289:1099–103.PubMedCrossRefGoogle Scholar
  112. 112.
    Greenstein AJ, Sachar DB, Smith H, Janowitz HD, Aufses AH, Jr. A comparison of cancer risk in Crohn disease and ulcerative colitis. Cancer 1981;48:2742–5.PubMedCrossRefGoogle Scholar
  113. 113.
    Gillen CD, Walmsley RS, Prior P, Andrews HA, Allan RN. Ulcerative colitis and Crohn disease: A comparison of the colorectal cancer risk in extensive colitis. Gut 1994;35:1590–2.PubMedCrossRefGoogle Scholar
  114. 114.
    Ekbom A, Helmick C, Zack M, Adami HO. Increased risk of large-bowel cancer in Crohn disease with colonic involvement. Lancet 1990;336:357–9.PubMedCrossRefGoogle Scholar
  115. 115.
    Sachar DB. Cancer in Crohn disease: Dispelling the myths. Gut 1994;35:1507–8.PubMedCrossRefGoogle Scholar
  116. 116.
    Ekbom A, Helmick C, Zack M, Adami HO. Extracolonic malignancies in inflammatory bowel disease. Cancer 1991;67:2015–9.PubMedCrossRefGoogle Scholar
  117. 117.
    Canavan C, Abrams KR, Mayberry J. Meta-analysis: Colorectal and small bowel cancer risk in patients with Crohn disease. Aliment Pharmacol Ther 2006;23:1097–104.PubMedCrossRefGoogle Scholar
  118. 118.
    Choi PM, Zelig MP. Similarity of colorectal cancer in Crohn disease and ulcerative colitis: Implications for carcinogenesis and prevention. Gut 1994;35:950–4.PubMedCrossRefGoogle Scholar
  119. 119.
    Friedman S, Rubin PH, Bodian C, Goldstein E, Harpaz N, Present DH. Screening and surveillance colonoscopy in chronic Crohn colitis. Gastroenterology 2001;120:820–6.PubMedCrossRefGoogle Scholar
  120. 120.
    Greenstein AJ, Gennuso R, Sachar DB, Heimann T, Smith H, Janowitz HD, Aufses AH, Jr. Extraintestinal cancers in inflammatory bowel disease. Cancer 1985;56:2914–21.PubMedCrossRefGoogle Scholar
  121. 121.
    Mir Madjlessi SH, Farmer RG, Weick JK. Inflammatory bowel disease and leukemia. A report of seven cases of leukemia in ulcerative colitis and Crohn disease and review of the literature. Dig Dis Sci 1986;31:1025–31.PubMedCrossRefGoogle Scholar
  122. 122.
    Cuttner J. Increased incidence of acute promyelocytic leukemia in patients with ulcerative colitis. Ann Intern Med 1982;97:864–5.PubMedGoogle Scholar
  123. 123.
    Persson PG, Karlen P, Bernell O, Leijonmarck CE, Brostrom O, Ahlbom A, Hellers G. Crohn disease and cancer: A population-based cohort study. Gastroenterology 1994;107:1675–9.PubMedGoogle Scholar
  124. 124.
    Wilkinson AH, Smith JL, Hunsicker LG, Tobacman J, Kapelanski DP, Johnson M, Wright FH, Behrendt DM, Corry RJ. Increased frequency of posttransplant lymphomas in patients treated with cyclosporine, azathioprine, and prednisone. Transplantation 1989;47:293–6.PubMedCrossRefGoogle Scholar
  125. 125.
    Opelz G, Henderson R. Incidence of non-Hodgkin lymphoma in kidney and heart transplant recipients. Lancet 1993;342:1514–6.PubMedCrossRefGoogle Scholar
  126. 126.
    Silman AJ, Petrie J, Hazleman B, Evans SJ. Lymphoproliferative cancer and other malignancy in patients with rheumatoid arthritis treated with azathioprine: A 20 year follow up study. Ann Rheum Dis 1988;47:988–92.PubMedCrossRefGoogle Scholar
  127. 127.
    Loftus EV, Jr., Tremaine WJ, Habermann TM, Harmsen WS, Zinsmeister AR, Sandborn WJ. Risk of lymphoma in inflammatory bowel disease. AmJ Gastroenterol 2000;95:2308–12.CrossRefGoogle Scholar
  128. 128.
    Korelitz BI, Mirsky FJ, Fleisher MR, Warman JI, Wisch N, Gleim GW. Malignant neoplasms subsequent to treatment of inflammatory bowel disease with 6-mercaptopurine. Am J Gastroenterol 1999;94:3248–53.PubMedCrossRefGoogle Scholar
  129. 129.
    Mackey AC, Green L, Liang LC, Dinndorf P, Avigan M. Hepatosplenic T cell lymphoma associated with infliximab use in young patients treated for inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2007;44:265–7.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2008

Authors and Affiliations

  • Thomas A. Ullman
    • 1
  1. 1.Assistant Professor of Medicine, The Dr. Henry D. Janowitz Division of GastroenterologyThe Mount S School of MedicineNew YorkUSA

Personalised recommendations